LEO Pharma

Astellas Pharma Europe | April 01, 2016

Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and LEO Pharma A/S (President and CEO: Gitte P. Aabo, “LEO Pharma”) today announced that the two companies completed the relevant closing conditions on March 31, 2016 to allow the transfer of the Astellas’ global dermatology business to LEO Pharma from 0 a.m. on April 1....

pharmatimes | July 20, 2017

A new treatment option has been approved in the European Union for patients with psoriasis, paving the way for access to a novel approach for those with moderate-to-severe forms of the disease who are candidates for systemic therapy. LEO Pharma’s Kyntheum (brodalumab) is a novel biologic and the first and only psoriasis treatment to target the L-17 receptor. By binding to this specific receptor on the cells of the skin, brodalumab blocks the biological activity of several pro-inflammatory IL-17 ...

Pharmaphorum Media Limited | October 29, 2018

LEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential in dermatology drug development. The pharmaceutical company’s Boston-based R&D innovation unit, the LEO Science & Tech Hub, will work on the device with Illinois’ Northwestern University’s Center for Bio-Integrated Electronics and its Wearifi spinout. Wearifi is developing the world’s smallest, battery-free wearable device, using miniaturized sen...

Pharmatimes | July 03, 2019

LEO Pharma has completed the acquisition of Bayer’s prescription dermatology business. The companies announced the proposal in July 2018, and completed the first step of the acquisition with the closing in the United States on September 4, 2018. Today’s second and final closing covers all other countries. Under the terms of the agreement, LEO Pharma has now acquired the global product rights for Bayer’s global prescription dermatology business with the exception of Afghanistan ...